We may be young, but we have a 20-year heritage of drug discovery, a broad portfolio of innovative drugs in the pipeline, an experienced team of over 800 professionals covering all disciplines from bench to bedside, and commercial operations in Europe and North America – the ideal constellation for bringing innovative medicines to patients.

We began our operations after demerging from Actelion following its acquisition by Johnson & Johnson in 2017. At that time, approximately 650 talented and engaged employees were transferred to Idorsia, together with the discovery pipeline and early-stage clinical assets.

Idorsia is specialized in the discovery, development, and commercialization of innovative medicines, with the aim of transforming the horizon of therapeutic options. We have a broad, diversified, and balanced portfolio, covering multiple therapeutic areas. Our portfolio comprises 1 marketed product and 10 assets in clinical development.

Idorsia is a start-up like no other!